gaining weight on retatrutide Why Am I Tesamorelin and Eli Lilly's retatrutide shows promising

Retatrutide is getting a lot of attention

New GLP1-based multi-agonist therapies seem to be substantially more effective than older GLP1R agonists in reducing body weight but their safety requires ongoing scrutiny in trials assessing outcomes in individuals with obesity

Do GLP-1 drugs help with fatty liver

This three-part synergy allows instant visible tightening while triggering long-term improvements in skin elasticity and texture

How big is the market

Eli Lilly said Thursday that its triple-agonist obesity drug retatrutide hit every primary and key secondary endpoint in TRIUMPH-1, the Phase 3 registration trial that will anchor the company's expected FDA filing